# High phosphate on FGFR inhibitors (erdafitinib, pemigatinib, futibatinib): monitoring, diet, binders and dose rules

Source: https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/  
OnCo record `hyperphosphataemia-on-fgfr-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Erdafitinib, pemigatinib and futibatinib raise blood phosphate in most people, usually in the first weeks. Phosphate is checked with blood tests. A rise is treated with a low-phosphate diet, tablets taken with food that bind phosphate, and sometimes a pause or a lower dose. Report cramps, tingling round the mouth or painful skin lumps. Your own team's plan comes first.

## Summary

FGFR1 signalling in the proximal tubule, driven by FGF23, limits phosphate reabsorption; blocking it raises serum phosphate. It is an expected pharmacodynamic effect: the US labels report raised phosphate in 73% of patients on erdafitinib (median onset 16 days), 93% on pemigatinib (8 days) and 88% on futibatinib (5 days), with phosphate binders used in 24% and 77% on erdafitinib and futibatinib and phosphate-lowering therapy in 33% on pemigatinib. Prolonged hyperphosphataemia can cause soft tissue mineralisation, cutaneous calcinosis, non-uraemic calciphylaxis and vascular calcification.

The three labels set different thresholds. Diet: erdafitinib restricts phosphate to 600 to 800 mg a day in everyone (US) or from 5.5 mg/dL, 1.75 mmol/L (EU); pemigatinib starts a low-phosphate diet above 5.5 mg/dL; futibatinib starts diet and a binder at 5.5 mg/dL or more. Binder: erdafitinib from 7 mg/dL (2.25 mmol/L) and pemigatinib above 7 mg/dL (both labels say phosphate-lowering therapy or a binder is started in their dose tables, and "consider" or "should be considered" in the erdafitinib warnings and the EU pemigatinib text). Dose: erdafitinib continues at 7 to 8.99 mg/dL, is withheld at 9 to 10 mg/dL (2.91 to 3.20 mmol/L) and restarted at the same dose, may be restarted one level lower after a value above 10 mg/dL, and is stopped for good if 10 mg/dL or more lasts over 2 weeks. Pemigatinib is continued while phosphate-lowering therapy is started, and withheld if phosphate is not under 7 mg/dL within 2 weeks of starting it or, when above 10 mg/dL, not 10 mg/dL or less within 1 week. Futibatinib is reduced, not withheld, above 7 mg/dL, and withheld above 10 mg/dL. Erdafitinib is also the only one whose dose is raised (8 to 9 mg) if phosphate is under 9.0 mg/dL at 14 to 21 days.

Choice of binder is opinion: the EU erdafitinib text suggests a non-calcium binder such as sevelamer; an unfunded review (Kommalapati 2021) prefers lanthanum or calcium-based binders when there is diarrhoea and says acetazolamide can be considered after the binder dose has been raised; an Incyte-sponsored review (Subbiah 2023) says calcium carbonate may be used unless calcium is raised, when sevelamer is preferred. All three EU texts warn of hypophosphataemia: the futibatinib text says binders and diet should be discontinued if treatment stops or phosphate falls below normal, the pemigatinib text says this should be considered during treatment breaks or if phosphate falls below normal, and the erdafitinib text says to discontinue them if phosphate falls below normal. No independent guideline was found.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: erdafitinib hyperphosphataemia; pemigatinib hyperphosphataemia; futibatinib hyperphosphataemia; FGFR inhibitor hyperphosphatemia; high phosphate on Balversa; high phosphate on Pemazyre; high phosphate on Lytgobi; low phosphate diet on FGFR inhibitors; phosphate binders with FGFR inhibitors

## Connected records

- targets: [FGFR1](https://onco.cc/targets/fgfr1/), [FGFR2](https://onco.cc/targets/fgfr2/)
- drugs: [Erdafitinib](https://onco.cc/drugs/erdafitinib/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/)
- pathways: [FGF / FGFR signalling](https://onco.cc/pathways/fgfr-signalling/)
- protocols: [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/), [Retinal and visual side effects of FGFR, MEK and ALK inhibitors and other targeted drugs: eye examinations and dose rules](https://onco.cc/protocols/retinal-and-eye-effects-on-fgfr-mek-and-alk-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/hyperphosphataemia-on-fgfr-inhibitors.json